Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes

摘要

The present invention provides novel pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.